Open call for nominations

Civil society representative members to the Guidance Development Groups WHO consolidated ARV guidelines process

29 August 2012

The World Health Organization (WHO) HIV Department is seeking nominations for two civil society representatives for three Guidelines Development Groups (GDG), as part of the process for developing the 2013 WHO consolidated antiretroviral (ARV) guidelines. The four Guidelines Development Groups are as follows:

  • Adults and adolescents (clinical guidelines);
  • Maternal and child health (clinical guidelines);
  • Operational guidelines (service delivery guidelines); and
  • Programmatic guidelines (appointment completed following consultation with civil society partners).

The role of the civil society representatives will be to join approximately 25 other experts from other sectors in providing additional technical input into the development of recommendations and operational guidance as part of the ongoing consolidated guidelines process.

It is expected that the nominees will have a good understanding of the relevant technical issues and practical experience relating to feasibility and implementation in resource-limited settings.

About the consolidated ARV guidelines process

The overall objective of these guidelines is to provide evidence-based recommendations on the use of ARVs in different populations along the continuum of HIV care. Based on the country experiences of implementing previous WHO HIV guidelines, and adapting them to country context and the latest developments in the field, the new 2013 guidelines will have a number of key features.

Unlike previous WHO HIV guidelines, the new update will move beyond clinical recommendations (What to do?) to include operational (How to do?) and programmatic (How to decide what to do and where?) recommendations to provide comprehensive guidance to national HIV programme managers, policymakers, implementers and donors.

  • The clinical component of the guidelines (one for adults and one for maternal and child health) will adopt a continuum-of-care approach. It will make recommendations on the diagnosis of HIV infection; the use of ARVs in HIV prevention; pre-antiretroviral therapy care; initiation and maintenance of first-, second- and third-line antiretroviral therapy (ART) regimens; monitoring for treatment failure, ARV toxicity and HIV drug resistance; management of co-infections and co-morbidities; and prevention and management of drug interactions. The needs of specific populations (such as pregnant women, children, people who use drugs, people with TB or active viral hepatitis) will be addressed in special sections.
  • The operational component will describe how ARV programmes can be implemented most efficiently and effectively. It will include recommendations on HIV testing approaches and strategies; models of chronic care; integration of HIV treatment and care with other services; decentralization of services; community engagement; task shifting; adherence to ART; and retention in care.
  • The programmatic component will provide guidance on how to support the translation of clinical and technical recommendations into policy and practice at national and local levels, as well as guidance on what parameters to consider when setting priorities and deciding on the implementation of the new recommendations. Strategic information needs will be addressed throughout the guidelines, including monitoring and evaluation of programmes, and operational research.

The 2013 consolidated guidelines will reflect the most current knowledge, available medicines, diagnostics and good practices for service delivery. HIV treatment is evolving rapidly, however, and new products and approaches will continue to become available after 2013. The HIV Department intends to update the consolidated guidelines every two years. When necessary, rapid guidance and technical and operational updates will complement the biennial updates. There will therefore be ongoing reviews to anticipate what guidance might be required for 2015 and 2017 guidelines, and beyond.

Roles and responsibilities of Guidelines Development Groups

Main activities of members of Guidelines Development Groups
  • Participate in periodic GDG teleconferences;
  • Review evidence summaries and assist in drafting recommendations;
  • Participate in face-to-face meeting of their GDG, to be held in Geneva in November and December 2012;
  • Review and comment on final draft guidelines in early to mid-2013;
  • Maintaining active communication with their co-Chairs and other members of the Guidelines Development Group; and
  • Ensure that key issues relevant to civil society are considered and addressed in the guidelines development process.
Remuneration and costs
  • WHO will be responsible for all costs related to your travel to relevant meetings (flights, accommodation, per diem) and participation in teleconferences
Availability for the Guidelines Development Group meetings (2012 tentative dates)
  • Operational and service delivery GDG: 6 – 8 November, 2012
  • Programmatic GDG: 28 – 30 November, 2012
  • Adult and Maternal and Child Health GDGs: 10 – 14 December, 2012

How to submit your nomination

Please express your interest in being appointed as a member of one of the GDG to Cadi Irvine ( and Chris Mallouris ( by 17:00 Geneva time, 14 September 2012.

In your application please:

  • Clarify for which Working Group the nomination is being made;
  • Include a brief letter of interest describing why you are interested in participating in this process and why you consider that you have the appropriate experience for the role; and
  • Include a copy of your most recent curriculum vitae.